



# Eterna Therapeutics Company Overview

January 2023

# Legal notices



This presentation (this “Presentation”) and any oral statements made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities of Eterna Therapeutics Inc., a Delaware corporation (including its consolidated subsidiaries and affiliates, the “Company”). The information contained herein does not purport to be all inclusive. The data contained herein is derived from various internal and external sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of such information. Any data on past performance contained herein is not an indication as to future performance. Except as required by applicable law, the Company assumes no obligation to update the information in this Presentation. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice. The communication of this Presentation is restricted by law, and it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation.

## **Forward-Looking Statements**

This Presentation includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, the Company’s expected plans and prospects, including without limitation, the Company’s views with respect to the potential for mRNA Cell Engineering, its expectations with respect to timing of regulatory filings and the reporting of initial data from any clinical trial(s), the potential therapeutic opportunities for mRNA Cell Engineering, its expectations regarding its product strategies, and its plans regarding commercialization of mRNA Cell Engineering. These forward-looking statements are distinguished by use of words such as “anticipate,” “aim,” “believe,” “continue,” “can,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and the negative of these terms, and similar references to future periods. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to, among other things, the Company’s ability to discover and develop novel drug candidates and delivery approaches, the Company’s ability to successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, the actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, the Company’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to the Company’s and others developing products for similar uses, the Company’s ability to manage operating expenses, the Company’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, the Company’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures.

Detailed information about these factors and additional important factors can be found in the documents that the Company files with the Securities and Exchange Commission, such as Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements speak only as of the date the statements were made. The Company does not undertake an obligation to update forward-looking information, except to the extent required by applicable law.

# Eterna vision




- We are a leading mRNA Cell Engineering platform based on a broad foundational intellectual property estate and will invest to realize its full potential
- We and our partners are discovering and developing an extraordinary breadth of valuable treatments to address some of the most fundamental diseases in medicine
- We intend to extend our cash runway and maximize our addressable market by entering high-value strategic collaborations
- We are a vibrant, interdisciplinary team committed to revolutionizing medicine



# The mRNA Cell Engineering platform



- Eterna has exclusively in-licensed an extensive portfolio of patents broadly covering foundational mRNA Cell Engineering technologies
- We expect that Eterna's patented technologies will be used in the most advanced cell engineering therapies in medicine
- We believe that Eterna's established insiders are committed to continued investment in the Eterna platform




# \$200B+ addressable market



- mRNA therapeutics<sup>1</sup>
- Cell therapy and tissue engineering<sup>2</sup>
- Genome editing<sup>3</sup>
- Genome editing technologies<sup>4</sup>

1. "mRNA: Therapeutics and Global Markets" (2021)  
<https://www.bccresearch.com/market-research/biotechnology/mrna-vaccines-and-therapeutics-market.html>
2. "Global Cell Therapy And Tissue Engineering Market Size By Material (Biologically Derived, Synthetic), By Type (Cell Therapy, Tissue Engineering), By Application (Genetic Diseases, Tissue Malignancy), By Geographic Scope And Forecast" (2021)  
<https://www.verifiedmarketresearch.com/product/cell-therapy-and-tissue-engineering-market/>
3. "Global Genome Editing Market Size & Share Report 2021-2028" (2019)  
<https://www.grandviewresearch.com/press-release/global-genome-editing-market>
4. "Global Genome Editing Technologies Market" (2022)  
<https://www.visiongain.com/report/genome-editing-technologies-market-2022/>



# Core strategy: High-value strategic partnering




- With over 100 foundational blocking in-licensed patents believed to cover both commercial and advanced clinical-stage products, Eterna is uniquely positioned to secure high-value strategic partnerships
- We have identified multiple public and private companies that we believe are currently using our patented technology and we believe will require a license to develop and commercialize products
- Eterna believes its patent estate will drive exceptional value creation for shareholders in coming years

## *Eterna's partnering strategy*

Manage technology and financing risk and accelerate therapeutic development by partnering assets, indications, and modalities

# Cells are the building blocks of life

Every organ and every tissue is made of and made by cells




Cells contain DNA, which stores genetic information

DNA is damaged by exposure to radiation, chemicals, and natural metabolism (aging)

Disease is caused by damage to cells

# Eterna's mRNA Cell Engineering Platform




Eterna's mRNA Cell Engineering platform addresses cellular dysfunction

ToRNAdo™ mRNA Delivery enables *in vivo* repair of cellular dysfunction

mRNA Gene Editing repairs genetic damage and confers new functionality to cells

mRNA Cell Reprogramming generates new cells

# mRNA Cell Engineering can generate many valuable products across diverse modalities



# Technology partnership with Factor Bioscience



## Patent License

- Exclusive license to over 100 foundational mRNA Cell Engineering patents
- License grants Eterna the right to enforce these patents against third-party infringers

## Master Services Agreement

- Access to Factor's research laboratory in Cambridge, MA, including state-of-the-art mRNA Cell Engineering equipment and training
- Provides immediate access to critical assets including protocols, formulations, sequences, templates, mRNA constructs, and iPS cells



# Leadership



**Matt Angel, PhD**  
Chief Executive  
Officer

- Co-Founder & CEO, Factor Bioscience
- Co-Founder, Exacis Biotherapeutics
- Co-Founder, Novellus Therapeutics



**Andrew Jackson**  
Chief Financial Officer

- Former CFO, Ra Medical Systems
- Former CFO, AltheaDx, Inc
- Former CFO, Celladon Corporation



**Roger Sidhu, MD**  
Chief Medical Officer

- Former Chief Medical Officer & VP, R&D, Roivant
- Former VP, Clinical Development, Kite Pharma
- Former Chief Medical Officer, Cell Design Labs



**Susan McClatchey**  
Vice President,  
Quality

- Former Sr. Director of Product Development, IQVIA
- Former Sr. Director of QA, ViaCyte
- Former Director of QA, Cosmo Bioscience



**Sandra Gurrola**  
Vice President,  
Finance

- Former VP, eGames.com
- Former VP of Finance, NTN Buzztime
- Former Sr. Manager of Finance, Metabasis Therapeutics

# Board of directors



**Charles Cherington**  
Chairman

- Co-Founder, Ara
- Co-Founder, Intervale Capital
- Founder, Cherington Capital



**Matt Angel, PhD**  
Chief Executive Officer

- Co-Founder & CEO, Factor Bioscience
- Co-Founder, Exacis Biotherapeutics
- Founder, Novellus Therapeutics



**Gregory Fiore, MD**  
Director

- CEO, Exacis Biotherapeutics
- Former CEO, Sollis Therapeutics
- Former CMO, The Medicines Company



**Nicholas Singer**  
Director

- Founder, Purchase Capital
- Founder, United Parks
- Executive Chairman, Only What You Need



**Bill Wexler**  
Director

- Chairman & CEO, Homer City Holdings
- Former Chairman & CEO, Upstate New York Power Products
- Former Chief Restructuring Officer, VMR Electronics



eterna